- Home
- TECX vs JPI Comparison
TECX vs JPI Comparison
Compare TECX & JPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- JPI
- Stock Information
- Founded
- TECX 2019
- JPI 2012
- Country
- TECX United States
- JPI United States
- Employees
- TECX N/A
- JPI N/A
- Industry
- TECX
- JPI Finance Companies
- Sector
- TECX
- JPI Finance
- Exchange
- TECX Nasdaq
- JPI Nasdaq
- Market Cap
- TECX 334.4M
- JPI 297.1M
- IPO Year
- TECX 2018
- JPI N/A
- Fundamental
- Price
- TECX $21.51
- JPI $20.21
- Analyst Decision
- TECX Buy
- JPI
- Analyst Count
- TECX 6
- JPI 0
- Target Price
- TECX $79.20
- JPI N/A
- AVG Volume (30 Days)
- TECX 172.8K
- JPI 54.7K
- Earning Date
- TECX 05-08-2025
- JPI 01-01-0001
- Dividend Yield
- TECX N/A
- JPI 6.15%
- EPS Growth
- TECX N/A
- JPI N/A
- EPS
- TECX N/A
- JPI N/A
- Revenue
- TECX N/A
- JPI N/A
- Revenue This Year
- TECX N/A
- JPI N/A
- Revenue Next Year
- TECX N/A
- JPI N/A
- P/E Ratio
- TECX N/A
- JPI N/A
- Revenue Growth
- TECX N/A
- JPI N/A
- 52 Week Low
- TECX $13.70
- JPI $16.02
- 52 Week High
- TECX $61.07
- JPI $19.12
- Technical
- Relative Strength Index (RSI)
- TECX 51.42
- JPI 50.50
- Support Level
- TECX $21.20
- JPI $19.87
- Resistance Level
- TECX $22.75
- JPI $20.40
- Average True Range (ATR)
- TECX 1.43
- JPI 0.34
- MACD
- TECX 0.01
- JPI -0.10
- Stochastic Oscillator
- TECX 41.32
- JPI 25.56
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.